The North America human vaccine adjuvants market was valued at US$ 656.08 million in 2022 and is expected to reach US$ 1.83 billion by 2030; it is estimated to register a CAGR of 13.7% from 2022 to 2030.
According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ?17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The rising geriatric population is also bolstering the demand for vaccines.
As per a study published in January 2023 by NCBI, in the US, the number of people aged 50 years and older will reach 221.13 million by 2050, a rapid increase from 137.25 million in 2020. People aged 50 and above are expected to suffer from at least one chronic disease, and the figure is projected to rise by 99.5% from 71.52 million in 2020 to 142.66 million by 2050. Also, it is projected that ~14 million people are likely to suffer from multimorbidity by 2050 The prevalence of hepatitis is also increasing.
Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030.hrough vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the North America human vaccine adjuvants market.
The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US.
According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea.
Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18.
Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the North America human vaccine adjuvants market growth in the US. The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country.
The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the North America human vaccine adjuvants market in the US.
Rising Prevalence of Chronic Diseases Fuels North America Human Vaccine Adjuvants Market
The rising prevalence of chronic diseases is fueling the demand for vaccine adjuvants. Adjuvants are added to vaccines to enhance the efficacy and body's immune response. They help improve the effectiveness of vaccines by stimulating a stronger and longer-lasting immune response. As the demand for vaccines to prevent and manage chronic diseases continues to grow, the demand for adjuvants also increases. Chronic diseases such as cardiovascular diseases, cancer, diabetes, and respiratory diseases are rising globally.According to the World Health Organization, the most noncommunicable disease-related deaths are cardiovascular diseases, accounting for ?17 million people each year, followed by cancers, chronic respiratory diseases, and diabetes (including deaths associated with the kidney). Furthermore, according to the World Heart Federation, high cholesterol causes 4.4 million deaths yearly, and ?24% of cardiovascular-related deaths are attributable to high low-density lipoprotein (LDL) cholesterol. Thus, the increasing burden of chronic diseases has led to a growing demand for vaccines that can prevent or manage these conditions. The rising geriatric population is also bolstering the demand for vaccines.
As per a study published in January 2023 by NCBI, in the US, the number of people aged 50 years and older will reach 221.13 million by 2050, a rapid increase from 137.25 million in 2020. People aged 50 and above are expected to suffer from at least one chronic disease, and the figure is projected to rise by 99.5% from 71.52 million in 2020 to 142.66 million by 2050. Also, it is projected that ~14 million people are likely to suffer from multimorbidity by 2050 The prevalence of hepatitis is also increasing.
Adjuvants in hepatitis vaccines aim to elicit robust and durable immunity, particularly in populations with suboptimal responses to standard vaccine formulations, such as those with underlying medical conditions or age-related immune senescence. According to the WHO, more than 350 million people worldwide live with hepatitis B or C. Among all types of hepatitis, several are preventable through vaccination. As per a study by WHO, an estimated 4.5 million premature deaths due to hepatitis could be prevented in low- and middle-income countries by 2030.hrough vaccination. Thus, the increasing prevalence of chronic diseases drives the growth of the North America human vaccine adjuvants market.
North America Human Vaccine Adjuvants Market Overview
The US holds a significant share of the North America human vaccine adjuvants market in North America. The market growth in this country is mainly ascribed to rising government spending on healthcare and a surging demand for novel vaccine formulations to treat infectious diseases more efficiently. According to the US Centers for Medicare & Medicaid Services, national healthcare expenditures in the US increased by 2.7% in 2021, reaching US$ 4.3 trillion or US$ 12,914 per person. Health spending accounted for 18.3% of the nation's GDP. As per the US Department of Health & Human Services, national health spending is expected to grow at an annual rate of 5.4% from 2019-2028, reaching US$ 6.2 trillion by 2028.The rising health expenditure may lead to a rise in funds allocation for the research and development of vaccines, fueling the demand for human vaccine adjuvants. According to new findings derived from the Global Burden of Disease study published in July 2020, there is a large and increasing burden of noncommunicable and infectious diseases in the US.
According to Johns Hopkins University, the cases of diseases such as SARS, Lyme disease, dengue fever, West Nile virus, and Zika virus infection have increased rapidly in the last two decades in the US. Also, the same source affirmed an increase in the incidence of re-emerging diseases such as malaria, tuberculosis, cholera, pertussis, influenza, pneumococcal disease, and gonorrhea.
Similarly, according to the Centers for Disease Control and Prevention (CDC), flu has resulted in 100,000 to 710,000 hospitalizations and 4,900 to 52,000 deaths annually between 2010 and 2022. According to a report by ICO/IARC Information Centre on HPV and Cancer in 2023, the US has a population of 140.5 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. Nearly 3.9% of women in the US in the general population are projected to harbor cervical HPV16/18 infection at a given time, and 71.2% of invasive cervical cancers are attributed to HPVs 16 or 18.
Thus, a rise in the incidences of various infections and re-emerging diseases boosts companies' efforts in vaccine development, fueling the North America human vaccine adjuvants market growth in the US. The US government strives to create a conducive environment for developing and commercializing pharmaceutical and healthcare products in the country.
The country has several potential pharmaceutical and medical device market players, including Pfizer, Novartis, Boston Scientific, Integra LifeSciences, Amgen, and Abbott, with various patents for their pharmaceutical and medical device industry innovations. Thus, an increase in drug development activities by various pharmaceutical giants bolsters the North America human vaccine adjuvants market in the US.
North America Human Vaccine Adjuvants Market Segmentation
The North America human vaccine adjuvants market is categorized into type, application, end user, and country.- Based on type, the North America human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.
- In terms of application, the North America human vaccine adjuvants market is categorized into influenza, hepatitis, human papilloma virus (HPV), and others. The influenza segment held the largest market share in 2022.
- By end user, the North America human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.
- By country, the North America human vaccine adjuvants market is segmented into the US, Canada, and Mexico. The US dominated the North America human vaccine adjuvants market share in 2022.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. North America Human Vaccine Adjuvants Market - Key Market Dynamics
5. Human Vaccine Adjuvants Market - North America Market Analysis
6. North America Human Vaccine Adjuvants Market Analysis - by Type
7. North America Human Vaccine Adjuvants Market Analysis - by Application
8. North America Human Vaccine Adjuvants Market Analysis - by End User
9. North America Human Vaccine Adjuvants Market - Country Analysis
10. Industry Landscape
11. Company Profiles
12. Appendix
Companies Mentioned
- Creative Biolabs Inc
- Croda International Plc
- CSL Ltd
- Dynavax Technologies Corp
- Hawaii Biotech Inc
- Novartis AG
- Novavax Inc
- Phibro Animal Health Corp
- Seppic SA
- SPI Pharma Inc
